There’s major progress happening in the fight against HSV-2. Assembly Biosciences (ASMB) has reported very promising interim results from two Phase 1b clinical studies testing their new investigational treatments for recurrent genital herpes — ABI-1179 and ABI-5366.
Here’s what stood out:
đź’Ą Key Clinical Results
ABI-1179 (weekly oral dosing):
91% reduction in confirmed genital lesions 99%+ drop in high-viral-load samples (the ones most linked to transmission) Well-tolerated up to 50 mg weekly
ABI-5366 (monthly dosing):
76% reduction in HSV-2 shedding 88% fewer genital lesions vs placebo Strong antiviral effects even with monthly dosing Weekly dosing cohorts previously showed up to 94% less shedding and 97% fewer lesions
👉 Both treatments remain investigational, and more research is needed — but these results are some of the most encouraging we’ve seen in years for HSV-2 therapies.
🔬 Why This Matters
Current HSV treatments manage symptoms — they don’t target viral shedding in an impactful new way. These early results suggest a potential shift in how herpes could be treated in the future.
Gilead also holds the option to license and advance these drugs, meaning we could see larger trials and faster development pathways.
📉 About the Company
Assembly Biosciences is a clinical-stage biotech company focused on antiviral therapeutics. While they are still early in development and working toward profitability, they maintain strong liquidity and ongoing partnerships. Like all biotech companies, progress depends heavily on clinical trial outcomes — but this update is a meaningful step forward.
⚠️ Important Note
These medications are not yet approved anywhere in the world. More studies are needed to confirm safety, effectiveness, and long-term outcomes.
This is a huge moment for anyone affected by HSV — patients, advocates, researchers, and communities everywhere who have been waiting for innovation in this space. 💜
If you want to stay updated on this research and other advancements, feel free to follow or share this post with others who could benefit.